Epilepsy is a significant healthcare burden in India, with an estimated 9.4 million people living with the condition

Epilepsy is a significant healthcare burden in India, with an estimated 9.4 million people living with the condition

Renocia Exo offers a new multitargeted approach to hair loss management by supporting the biology of the hair follicle-not just hair growth

The company is the first company in India to introduce semaglutide in single-shot pre-filled syringe format

Consolidated total income of the company increased by 15.61% at Rs 3,803.39 crore for Q4FY26

At the end of the inspection, no form 483 was issued

The new entity has been incorporated with a view to export the company’s products to African, South East Asian and non-UAE markets

The product is approved by the Food Safety Standards Authority of India

Alkem Pharmaceuticals has been incorporated to undertake the activities of manufacturing products and obtaining product registrations, except trading activities

The company has launched its semaglutide pre-filled disposable injection pen at a price starting Rs 1,800 for a month’s dosage, which translates into a weekly cost of Rs 450

The said certificate is valid for a period of three years from the date of inspection

The consolidated total income of the company increased by 11.90% at Rs 3,879.92 crore for Q3FY26

The consolidated total income of the company increased by 11.90% at Rs 3,879.92 crore for Q3FY26

At the conclusion of the inspection, the USFDA issued a Form 483 with 6 procedural observations

This acquisition represents a significant step in Alkem MedTech’s journey to build a global footprint and enables its entry into advanced cardiovascular devices

Renocia cyclical therapy is formulated separately for men and women to match their specific nutritional needs and available in separate kits

The said inspection was conducted from December 05, 2025 and concluded on December 09, 2025

Alkem’s DSS range will be available in four strengths - 225 billion CFU sachet, 112.5 billion CFU capsule, 45 billion CFU capsule, and 10 billion CFU capsule

The said inspection was concluded on November 10, 2025 with no critical or major observations

The company had launched ’Pertuza’ injection

Alkem’s Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab

Alkem’s Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab

The company already has a strong presence in the moisturizer segment with its Olesoft range of products

The company already has a strong presence in the moisturizer segment with its Olesoft range of products

Pursuant to incorporation of such subsidiary, the company will hold 51% of the total share capital

The company’s arm has executed Share Purchase and Share Subscription Agreement

The company’s arm has executed Share Purchase and Share Subscription Agreement

At the end of the inspection, no Form 483 was issued

This ’Empanorm’ is use for the treatment of type-2 diabetes mellitus, chronic kidney disease (CKD) and chronic heart failure (HF)

Total consolidated income of the company increased by 1.46% at Rs 3467.27 crore for Q3FY25

With the introduction of Kojiglo serum, Alkem aims to broaden its portfolio and increase its market share in the skincare segment

With the introduction of Kojiglo serum, Alkem aims to broaden its portfolio and increase its market share in the skincare segment

The sale is part of an ongoing initiative of networking strategy and optimisation of manufacturing facilities

The said investment will be completed by the end of April, 2025

The said investment will be completed by the end of April, 2025

The Board of Directors of Alkem Laboratories at its meeting held on December 10, 2024 has approved the same

The Board of Directors of Alkem Laboratories at its meeting held on December 10, 2024 has approved the same

The licensing agreement is to develop, manufacture and commercialise the drug candidate ‘SON-080’ for the treatment of diabetic peripheral neuropathy in India

The licensing agreement is to develop, manufacture and commercialise the drug candidate ‘SON-080’ for the treatment of diabetic peripheral neuropathy in India

Alkem Wellness has been incorporated to carry on the business in all kinds of drugs, pharmaceuticals, drugs formulation, etc

Alkem Medtech has been incorporated for exploring the medical device segment mainly in the cardiovascular and orthopedic fields

At the end of the inspection, the company has received Form 483 with 10 observations

The inspection has been classified as Voluntary Action Indicated and was closed accordingly

All rights, title and interest in the land, improvements and personal property with respect to the said Facility are sold to M/s New Mill Capital Holdings LLC

At the end of the inspection, the Company has received Form 483 with three observations

Total consolidated income of the company increased by 15.44% at Rs 3,033.56 crore for Q1FY24

The nationwide launch of the company’s ophthalmology product range ensures that patients across India have access to quality eye-care formulations

The introduction of the medication is in line with the company’s endeavour to ensure affordability, accessibility and availability

Total consolidated income of the company increased by 18.64% at Rs 2,971.27 crore for Q4FY23

At the end of the inspection, no Form 483 was issued

The inspection has now been closed by the USFDA

Total consolidated income of the company increased by 15.48% to Rs 3,086.24 crore for Q3FY23

Total consolidated income of the company increased by 15.48% to Rs 3,086.24 crore for Q3FY23

The company’s product Zidavi is a novel combination of ceftazidime & avibactam

Total consolidated income of the company increased by 10.14% to Rs 3,130.04 crore for Q2FY23

USFDA has issued Form 483 with 3 observations to Alkem Laboratories’ St Louis plant

At the end of the inspection, the company received Form 483 with three observations

Alkem’s Dapanorm Trio will have a significant role in reducing HbA1c in uncontrolled type 2 diabetic patients

At the end of the inspection, the company has received Form 483 with two observations

The USFDA had conducted a Good Manufacturing Practice and pre-approval inspection from July, 1 2022 to July 7, 2022

At the end of the inspection, the company has received Form 483 with three observations